


PTSD does not discriminate and affects the lives of millions.The SGB treatment protocol has a reported 83% effective rate using our patented drug CLONICAINE.
The duration and level of relief varies among patients and is contingent upon many factors. Some patients will not experience any relief from their symptoms post SGB treatment.
CAD owns several Patents that cover both the SGB injection Method (Route of Administration) using the Drug CLONICAINE.
CLONICAINE is not an approved FDA drug for on-label for the treatment of PTSD indication.
CLONICAINE is only available to patients as part of an FDA Phase 2b clinical study that starts recruitment in Q1 2026.

- Combat/Warfare
- Childhood Abuse / Experience
- Sexual Assault
- Response to Health Issues
- Injury or Death of Loved One
- Domestic Violence
- Physical Violence or Threat
- Witness to Traumatic Event
- Other trauma
6 Saint John's Lane, New York, New York 10013, United States